Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun;85(6):1208-1212.
doi: 10.1111/bcp.13791. Epub 2018 Dec 3.

Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective

Theresa Kehoe  1 , Eberhard Blind  2 , Heidi Janssen  2
Affiliations
Review

Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective

Theresa Kehoe et al. Br J Clin Pharmacol. 2019 Jun.

Abstract

Regulation of medicines involves complex scientific and public health policies which are reflected in the regulatory approaches used by the European Medicines Agency and the United States Food and Drug Administration for the approval of products developed for metabolic bone diseases. For osteoporosis therapies, utilized by many patients, the approaches and existing guidance for product development of both agencies are similar; confirmatory studies for the approval of osteoporosis products can rely on well-defined efficacy outcome parameters. Therapeutics for rare bone diseases, a rapidly expanding area, often require an individualized regulatory approach. This review outlines key aspects of these regulatory approaches applied by the two agencies for products for metabolic bone diseases.

Keywords: drug regulation; metabolic bone disease; osteoporosis; public health.

PubMed Disclaimer

Conflict of interest statement

There are no competing interests to declare.

The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties or on behalf of or reflecting the position of the US Food and Drug Administration.

References

    1. EMA . The European regulatory system for medicines. 2016. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2014/08/WC5... (last accessed 21 June 2018).
    1. ICH . International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines. Available at http://www.ich.org/products/guidelines.html (last accessed 21 June 2018).
    1. Annotated guidance to the European Medicines Agency (EMA) guidelines and regulatory documents. A new series of the BJCP. [Editorial]. Br J Clin Pharmacol 2018; 84: 1399. - PMC - PubMed
    1. US Food and Drug Administration . FDA Basics for Industry. Guidances. Available at https://www.fda.gov/ForIndustry/FDABasicsforIndustry/ucm234622.htm (last accessed 21 June 2018).
    1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al Effect of parathyroid hormone (1‐34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–1441. - PubMed

MeSH terms

Substances